Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Lenvatinib 18 mg Plus Everolimus 5 mg	357
Overall Study	STARTED	Lenvatinib 20 mg Plus Pembrolizumab 200 mg	355
Overall Study	STARTED	Sunitinib 50 mg	357
Overall Study	Treated	Lenvatinib 18 mg Plus Everolimus 5 mg	355
Overall Study	Treated	Lenvatinib 20 mg Plus Pembrolizumab 200 mg	352
Overall Study	Treated	Sunitinib 50 mg	340
Overall Study	COMPLETED	Lenvatinib 18 mg Plus Everolimus 5 mg	0
Overall Study	COMPLETED	Lenvatinib 20 mg Plus Pembrolizumab 200 mg	0
Overall Study	COMPLETED	Sunitinib 50 mg	0
Overall Study	NOT COMPLETED	Lenvatinib 18 mg Plus Everolimus 5 mg	357
Overall Study	NOT COMPLETED	Lenvatinib 20 mg Plus Pembrolizumab 200 mg	355
Overall Study	NOT COMPLETED	Sunitinib 50 mg	357

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02811861/flow